参考文献/References:
[1] Hayashi M,Shimizu W,Albert CM. The spectrum of epidemiology underlying sudden cardiac death[J]. Circ Res,2015,116(12):1887-1906.
[2] Miller JD,Yousuf O,Berger RD. The implantable cardioverter-defibrillator:an update[J]. Trends Cardiovasc,2015,25(7):606-611.
[3] Hua W,Zhang LF,Wu YF,et al. Incidence of sudden cardiac death in China:analysis of 4 regional populations[J]. J Am Coll Cardiol,2009,54(12):1110-1118.
[4] 易甫,吴宾,郭兰燕,等. 心脏性猝死与植入型心脏转复除颤器[J]. 心脏杂志,2017,29(4):470-473,475.
[5] Feng XF,Hai JJ,Ma Y,et al. Sudden cardiac death in Mainland China[J]. Circ Arrhythm Electrophysiol,2018,11(11):e006684.
[6] Elayi CS,Charnigo RJ,Heron PM,et al. Primary prevention of sudden cardiac death early post-myocardial infarction:root cause analysis for implantable cardioverter-defibrillator failure and currently available options[J]. Circ Arrhythm Electrophysiol,2017,10(6):e005194.
[7] Wit AL. Basic Electrophysiologic mechanisms of sudden cardiac death caused by acute myocardial ischemia and infarction [J]. Card Electrophysiol Clin,2017,9(4):525-536.
[8] Kolettis TM,Kontonika M,Lekkas P,et al. Autonomic responses during acute myocardial infarction in the rat model:implications for arrhythmogenesis[J]. J Basic Clin Physiol Pharmacol,2018,29(4):339-345.
[9] Buxton AE,Lee KL,Fisher JD,et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators[J]. N Engl J Med,1999,341(25):1882-1890.
[10] Moss AJ,Zareba W,Hall WJ,et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction[J]. N Engl J Med,2002,346(12):877-883.
[11] Goldenberg I,Gillespie J,Moss AJ,et al. Long-term benefit of primary prevention with an implantable cardioverter defibrillator:an extended 8-year follow-up study of the multicenter automatic defibrillator implantation trialⅡ[J]. Circulation,2010,122(13):1265-1271.
[12] Piccini JP Sr,Allen LA,Kudenchuk PJ,et al. Wearable cardioverter-defibrillator therapy for the prevention of sudden cardiac death:a science advisory from the American Heart Association[J]. Circulation ,2016,133(17):1715-1727.
[13] Al-Khatib SM,Stevenson WG,Ackerman MJ,et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the hear[J]. Heart Rhythm,2018,15(10):e190-252.
[14] Epstein AE,Abraham WT,Bianco NR,et al. Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction[J]. Journal of the American College of Cardiology,2013,62(21):2000-2007.
[15] Kaspar G,Sanam K,Gholkar G,et al. Long-term use of the wearable cardioverter defibrillator in patients with explanted ICD[J]. Int J Cardiol,2018,272:179-184.
[16] 鲁仲巧,范洁. 全皮下植入式心律转复除颤器在室性心律失常中的治疗进展[J]. 心血管病学进展,2019,40(2):301-304.
[17] Ezzat VA,Lee V,Ahsan S,et al. A systematic review of ICD complications in randomised controlled trials versus registries:is our ‘real-world’ data an underestimation?[J]. Open Heart,2015,2(1):e000198.
[18] Basu-Ray I,Liu J,Jia X ,et al. Subcutaneous versus transvenous implantable defibrillator therapy:a meta-analysis of case-control studies[J]. JACC Clin Electrophysiol ,2017,3(13):1475-1483.
[19] Boersma L,Barr C,Knops R,et al. Implant and midterm outcomes of the subcutaneous implantable cardioverter-defibrillator registry[J]. J Am Coll Cardiol,2017,70(7):830-841.
[20] Baalman SWE,Quast ABE,Brouwer TF,et al. An overview of clinical outcomes in transvenous and subcutaneous ICD patients [J]. Curr Cardiol Rep,2018,20(9):72.
[21] Russo RJ,Costa HS,Silva PD,et al. Assessing the risks associated with MRI in patients with a pacemaker or defibrillator [J]. N Engl J Med,2017,376(8):755-764.
[22] Singh A,Kawaji K,Goyal N,et al. Feasibility of cardiac magnetic resonance wideband protocol in patients with implantable cardioverter defibrillators and its utility for defining scar[J]. Am J Cardiol,2019,123(8):1329-1335.
相似文献/References:
[1]王铁华,郑景辉,莫云秋.蛋白质组学在心肌梗死中的研究进展[J].心血管病学进展,2015,(5):616.[doi:10.3969/j.issn.1004-3934.2015.05.024]
WANG Tiehua,ZHENG Jinghui,MO Yunqiu.Research Progress of Proteomics in Myocardial Infarction[J].Advances in Cardiovascular Diseases,2015,(1):616.[doi:10.3969/j.issn.1004-3934.2015.05.024]
[2]刘颖,袁美锦.儿童与青少年心脏性猝死的病因和预防[J].心血管病学进展,2019,(6):935.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.024]
LIU Ying,YUAN Meijin.Causes and Prevention of Sudden Cardiac Death in Children and Adolescents[J].Advances in Cardiovascular Diseases,2019,(1):935.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.024]
[3]孙洋.基质金属蛋白酶与心肌梗死后心脏重构[J].心血管病学进展,2019,(8):1094.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.006]
SUN Yang.Matrix Metalloproteinases in Cardiac Remodeling after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(1):1094.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.006]
[4]陈丰 苏强 朱继金.高迁移率族蛋白B1在心脏炎症反应性疾病中的研究进展[J].心血管病学进展,2019,(8):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
CHEN Feng,SU Qiang,ZHU Jijin.Research Progress of HMGB1 in Myocardial Inflammatory Reactivity Disease[J].Advances in Cardiovascular Diseases,2019,(1):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
[5]常文婧 王丽娜.Hippo通路在心脏发育、再生和疾病中的作用[J].心血管病学进展,2019,(8):1115.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.011]
CHANG Wenjin,WANG Lina.Role of Hippo Pathway in Heart Development,Regeneration and Disease[J].Advances in Cardiovascular Diseases,2019,(1):1115.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.011]
[6]邹先明 赵然尊.长链非编码RNA ANRIL与心血管疾病的研究进展[J].心血管病学进展,2020,(2):167.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
ZOU Xianming,ZHAO Ranzun.Long Non-Coding RNA ANRIL and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(1):167.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
[7]鲁星琴 莫乔莹 陈凤梅 姚亚丽.睡眠呼吸障碍与心力衰竭并发心房颤动的相关性研究现状[J].心血管病学进展,2020,(2):182.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.021]
LU Xingqin,MO Qiaoying,CHENG Fengmei,et al.Research Status of Association Between Sleep-disordered Breathing and Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2020,(1):182.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.021]
[8]王茜 李晶洁.细胞学机制在调控心肌梗死后炎症反应中的研究进展[J].心血管病学进展,2020,(2):190.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.023]
WANG QianLI Jingjie.Cytological Mechanisms in Regulation of The Post-infarction Inflammatory Response[J].Advances in Cardiovascular Diseases,2020,(1):190.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.023]
[9]黄柳,张瑞宁,田小超,等.内皮祖细胞与冠心病患者CD14CD16+单核细胞共培养后移植心肌梗死大鼠对血管密度及心肌梗死面积的影响[J].心血管病学进展,2020,(2):203.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.027]
HUANG Liu,ZHANG Ruining,TIAN Xiaochao,et al.Effects of Co-cultured Endothelial Progenitor Cells and CD14++CD16+ Monocytes from Coronary Heart Disease Patients on Vascular Density and Myocardial Infarction Size in Transplanting Myocardial Infarction Rats[J].Advances in Cardiovascular Diseases,2020,(1):203.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.027]
[10]刘玉婷,贾锋鹏.骨膜蛋白与心血管疾病的研究进展[J].心血管病学进展,2020,(3):239.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.006]
LIU Yuting,JIA Fengpeng.Roles of Periostin in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(1):239.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.006]
[11]王思博 王连生.心肌梗死后室性心律失常的治疗进展[J].心血管病学进展,2021,(6):481.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.001]
WANG SiboWANG Liansheng.Treatment of Ventricular Arrhythmias after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(1):481.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.001]